
GlycoNex, Inc.
New Taipei City, Taiwan glyconex.com.tw From their website, Nov 2026
- GMP
Work here? Claim this listing
About
GlycoNex, Inc. is a clinical-stage biopharmaceutical company in New Taipei City, Taiwan. It develops antibody-based therapeutics focused on glycan-directed cancer immunotherapy, and also provides antibody CDMO services and biosimilar development.
GlycoNex, Inc. is a CRDMO in New Taipei City, Taiwan, founded in 2001. It lists 10 services, including Cell line development, Process development and scale-up and GMP-compliant antibody manufacturing. It names GMP on its listing.
Services
Cell line development
Establishes stable cell lines and selects clones for antibody and antibody-based modalities.
Cell line development
Process development and scale-up
Develops and optimizes upstream and downstream processes and scales them up for manufacturing.
GMP-compliant antibody manufacturing
Produces antibodies at 50 L and 200 L scale for Phase 1 clinical supply.
CDMO: development & manufacturing
Technology transfer
Provides structured transfer and project management from development to manufacturing.
Analytical development
Supports development, characterization, and quality control of monoclonal antibodies and antibody-drug conjugates.
Glycan isolation and purification
Isolates and purifies glycans from biological materials for characterization, screening, and research.
Glycan semi-synthesis
Prepares and structurally modifies glycans from naturally derived carbohydrate materials.
Glycan structure analysis
Characterizes glycan composition, branching patterns, linkages, and other structural features.
2 more services
- Glycosylation-site analysis
- Monosaccharide analysis
How to order from GlycoNex, Inc.
They take quote requests by email. You can contact them directly from this page, or request a quote through Midgard.
Capabilities
- Assays and studies
- Antibodies
- ADCs
- Process development
- HPLC
- Bispecifics
- Analytical development
15 more
- SPR
- ELISA
- Cell-based assays
- SEC-HPLC
- CIEX / AEX-HPLC
- SDS-PAGE
- CE-SDS
- RP-HPLC
- cIEF
- Protein A-HPLC
- A280
- ADCC / CDC
- Intact-protein MS
- Peptide mapping
- PTM profiling
- Scale and capacity
- 50 L pilot-scale
- 200 L GMP-compliant manufacturing
- 50 L + 200 L GMP antibody facility
- Therapeutic areas
- Oncology
- GI cancers
- Solid tumors
- Osteoporosis
- Autoimmune disease
Instruments and platforms
- SEC-HPLC
- CIEX / AEX-HPLC
- SDS-PAGE
- CE-SDS
- RP-HPLC
- cIEF
7 more
- Protein A-HPLC
- A280
- ELISA
- SPR
- Intact-protein MS
- CD
- DSC
Modalities and species
- Modalities
- Antibody
- Bispecific
- ADC
- Biosimilar
- Species and models
- GI cancers
- Solid tumors
- Osteoporosis
- Autoimmune disease
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: antibody manufacturing
GLPSelf-reported
Details
- Type
- CRDMO
- Founded
- 2001
- Based in
- New Taipei City, Taiwan
- Sites
- Taipei, Taiwan
- Serves
- Taiwan, Japan